Insight on the Side Effects of Lipid Lowering Agents (Statin) in Iraqi Patients with Ischemic Heart Diseases
Iraqi Postgraduate Medical Journal,
2009, Volume 8, Issue 3, Pages 266-269
3-hydroxy-3methyl glutaryl co enzyme inhibitor (MMG-COA) (statin) is a very common drug used in many medical conditions regardless of the presence or absence of dyslipidemia. One of these conditions is the cardiac disorders.
Throwing a light on the prevalence of their side effects in Iraqi patients.
PATIENTS AND METHODS:
Two hundred seventy patients with ischemic heart disease from the period of November 2006-November 2007 referred to Baghdad teaching hospital (the medical city). Those cases were using statin and grouped into two groups.
Group A: patients admitted with acute coronary syndrome (myocardial infarction and unstable angina) (230 patients 77%).
Group B: patients with associated risk factors (Hypertension, diabetes mellitus, smoking and secondary lipidemia) 40 cases 23%, have history of ischemic heart disease on treatment they use the drug in range of (10-40) daily with review monthly for the side effects. All 270 cases were free from other organic disorders (i.e. renal, thyroid, malignancy, or any longstanding disease). All patients went through a questionnaire which includes: age, gender, risk factors (Hypertension, diabetes mellitus, smoking, and lipidemia), routine blood tests, lipid profile, liver function tests, C-reactive proteins, thyroid function tests, chest X-ray, electrocardiography and echocardiography done for all patients, all patients used to take drugs in the range of 10-40mg daily for at least one year.
The side effects noticed in this study were gastric, musculoskeletal, elevated liver enzymes (40%, 28.9%, and 1% respectively from the total number of patients). Other side effects in other systems like skin, respiratory, and cardiac were not encountered.
This study showed that the side effects of statin were not involving all the body systems.
- Article View: 157
- PDF Download: 103